Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
17,797
archived clinical trials in
Peripheral Vascular Disease

Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated:  12/13/2012
Novartis Investigative Site
mi
from
Omaha, NE
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated: 12/13/2012
Novartis Investigative Site
mi
from
Omaha, NE
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated:  12/13/2012
Novartis Investigative Site
mi
from
Brick, NJ
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated: 12/13/2012
Novartis Investigative Site
mi
from
Brick, NJ
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated:  12/13/2012
Novartis Investigative Site
mi
from
Albuquerque, NM
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated: 12/13/2012
Novartis Investigative Site
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated:  12/13/2012
Novartis Investigative Site
mi
from
Mineola, NY
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated: 12/13/2012
Novartis Investigative Site
mi
from
Mineola, NY
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated:  12/13/2012
Novartis Investigative Site
mi
from
High Point, NC
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated: 12/13/2012
Novartis Investigative Site
mi
from
High Point, NC
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated:  12/13/2012
Novartis Investigative Site
mi
from
Bismark, ND
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated: 12/13/2012
Novartis Investigative Site
mi
from
Bismark, ND
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated:  12/13/2012
Novartis Investigative Site
mi
from
Cincinatti, OH
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated: 12/13/2012
Novartis Investigative Site
mi
from
Cincinatti, OH
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated:  12/13/2012
Novartis Investigative Site
mi
from
Oklahoma City, OK
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated: 12/13/2012
Novartis Investigative Site
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated:  12/13/2012
Novartis
mi
from
Portland, OR
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated: 12/13/2012
Novartis
mi
from
Portland, OR
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated:  12/13/2012
Novartis Investigative Site
mi
from
Blue Bell, PA
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated: 12/13/2012
Novartis Investigative Site
mi
from
Blue Bell, PA
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated:  12/13/2012
Novartis Investigative Site
mi
from
Knoxville, TN
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated: 12/13/2012
Novartis Investigative Site
mi
from
Knoxville, TN
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated:  12/13/2012
Novartis Investigative site
mi
from
Dallas, TX
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated: 12/13/2012
Novartis Investigative site
mi
from
Dallas, TX
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated:  12/13/2012
Novartis Investigative Site
mi
from
Salt Lake City, UT
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated: 12/13/2012
Novartis Investigative Site
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Evaluation Using ClearView in Determining Association to the Cardiac Risk Factors
Evaluation Using ClearView in Determining Association to the Cardiac Risk Factors (Cardiac-CV)
Status: Enrolling
Updated:  12/13/2012
Mission Internal Medical Group
mi
from
Mission Viejo, CA
Evaluation Using ClearView in Determining Association to the Cardiac Risk Factors
Evaluation Using ClearView in Determining Association to the Cardiac Risk Factors (Cardiac-CV)
Status: Enrolling
Updated: 12/13/2012
Mission Internal Medical Group
mi
from
Mission Viejo, CA
Click here to add this to my saved trials
Coronary Disease Morbidity and Mortality in a Population
Coronary Disease Morbidity and Mortality in a Population
Status: Enrolling
Updated:  12/17/2012
St Marys Hospital
mi
from
Rochester, MN
Coronary Disease Morbidity and Mortality in a Population
Coronary Disease Morbidity and Mortality in a Population
Status: Enrolling
Updated: 12/17/2012
St Marys Hospital
mi
from
Rochester, MN
Click here to add this to my saved trials
Coronary Disease Morbidity and Mortality in a Population
Coronary Disease Morbidity and Mortality in a Population
Status: Enrolling
Updated:  12/17/2012
Rochester Methodist Hospital
mi
from
Rochester, MN
Coronary Disease Morbidity and Mortality in a Population
Coronary Disease Morbidity and Mortality in a Population
Status: Enrolling
Updated: 12/17/2012
Rochester Methodist Hospital
mi
from
Rochester, MN
Click here to add this to my saved trials
Safety & Effectiveness on Vascular Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT Patients
A Multi Center, Randomized , Double Blind, Placebo-controlled, Study of the Safety, Tolerability, and Effects on Arterial Structure and Function of ACZ885 in Patients With Clinically Evident Atherosclerosis and Either T2DM or IGT
Status: Enrolling
Updated:  12/18/2012
Novartis Investigative Site
mi
from
Mineola, NY
Safety & Effectiveness on Vascular Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT Patients
A Multi Center, Randomized , Double Blind, Placebo-controlled, Study of the Safety, Tolerability, and Effects on Arterial Structure and Function of ACZ885 in Patients With Clinically Evident Atherosclerosis and Either T2DM or IGT
Status: Enrolling
Updated: 12/18/2012
Novartis Investigative Site
mi
from
Mineola, NY
Click here to add this to my saved trials
Safety & Effectiveness on Vascular Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT Patients
A Multi Center, Randomized , Double Blind, Placebo-controlled, Study of the Safety, Tolerability, and Effects on Arterial Structure and Function of ACZ885 in Patients With Clinically Evident Atherosclerosis and Either T2DM or IGT
Status: Enrolling
Updated:  12/18/2012
Novartis Investigative Site
mi
from
Cincinatti, OH
Safety & Effectiveness on Vascular Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT Patients
A Multi Center, Randomized , Double Blind, Placebo-controlled, Study of the Safety, Tolerability, and Effects on Arterial Structure and Function of ACZ885 in Patients With Clinically Evident Atherosclerosis and Either T2DM or IGT
Status: Enrolling
Updated: 12/18/2012
Novartis Investigative Site
mi
from
Cincinatti, OH
Click here to add this to my saved trials
SCRIPPS V: Intracoronary Brachytherapy for Recurrent Restenosis After Multiple Drug-Eluting Stents
Intracoronary Brachytherapy for Recurrent Restenosis After Multiple Drug-Eluting Stents. Short Title: Scripps V
Status: Enrolling
Updated:  12/20/2012
Scripps Green Hospital/Scripps Clinic
mi
from
La Jolla, CA
SCRIPPS V: Intracoronary Brachytherapy for Recurrent Restenosis After Multiple Drug-Eluting Stents
Intracoronary Brachytherapy for Recurrent Restenosis After Multiple Drug-Eluting Stents. Short Title: Scripps V
Status: Enrolling
Updated: 12/20/2012
Scripps Green Hospital/Scripps Clinic
mi
from
La Jolla, CA
Click here to add this to my saved trials
Effect of GLP-1 on Postprandial Lipid Metabolism
The Role of GLP-1 in Lipid Metabolism in Healthy Subjects and in Subjects After Bariatric Surgery
Status: Enrolling
Updated:  1/2/2013
Veteran's Affairs Clinical Research Unit
mi
from
Cincinnati, OH
Effect of GLP-1 on Postprandial Lipid Metabolism
The Role of GLP-1 in Lipid Metabolism in Healthy Subjects and in Subjects After Bariatric Surgery
Status: Enrolling
Updated: 1/2/2013
Veteran's Affairs Clinical Research Unit
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Effect of Xenon and Therapeutic Hypothermia, on the Brain and on Neurological Outcome Following Brain Ischemia in Cardiac Arrest Patients
Phase 2 Study of Effect of Xenon, in Combination With Therapeutic Hypothermia, on the Brain and on Neurological Outcome Following Brain Ischemia in Cardiac Arrest Patients
Status: Enrolling
Updated:  1/4/2013
Department of Anesthesia and Perioperative Care
mi
from
San Fransisco, CA
Effect of Xenon and Therapeutic Hypothermia, on the Brain and on Neurological Outcome Following Brain Ischemia in Cardiac Arrest Patients
Phase 2 Study of Effect of Xenon, in Combination With Therapeutic Hypothermia, on the Brain and on Neurological Outcome Following Brain Ischemia in Cardiac Arrest Patients
Status: Enrolling
Updated: 1/4/2013
Department of Anesthesia and Perioperative Care
mi
from
San Fransisco, CA
Click here to add this to my saved trials
Care4U: Self Management Intervention for Older Adult Caregivers
Status: Enrolling
Updated:  1/8/2013
Bryan Health
mi
from
Lincoln, NE
Care4U: Self Management Intervention for Older Adult Caregivers
Status: Enrolling
Updated: 1/8/2013
Bryan Health
mi
from
Lincoln, NE
Click here to add this to my saved trials
A Comparison of the Effects of Intraoperative Administration of Metoprolol or Esmolol on General Anesthetic Requirement
A Comparison of the Effect of Intraoperative Administration of Metoprolol or Esmolol on General Anesthetic Requirement
Status: Enrolling
Updated:  1/15/2013
Univeristy of Oklahoma Health Sciences Center Dept. Anesthesiology
mi
from
Oklahoma, OK
A Comparison of the Effects of Intraoperative Administration of Metoprolol or Esmolol on General Anesthetic Requirement
A Comparison of the Effect of Intraoperative Administration of Metoprolol or Esmolol on General Anesthetic Requirement
Status: Enrolling
Updated: 1/15/2013
Univeristy of Oklahoma Health Sciences Center Dept. Anesthesiology
mi
from
Oklahoma, OK
Click here to add this to my saved trials
Seattle Cardiorenal Remote Ischemic Preconditioning Trial
Effect of Remote Ischemic Preconditioning in Children Undergoing Cardiac Surgery
Status: Enrolling
Updated:  1/15/2013
Seattle Children's Hospital
mi
from
Seattle, WA
Seattle Cardiorenal Remote Ischemic Preconditioning Trial
Effect of Remote Ischemic Preconditioning in Children Undergoing Cardiac Surgery
Status: Enrolling
Updated: 1/15/2013
Seattle Children's Hospital
mi
from
Seattle, WA
Click here to add this to my saved trials
The Effect of Ventilation on Cerebral Oxygenation in the Sitting Position
Status: Enrolling
Updated:  1/15/2013
NorthShore University HealthSystem
mi
from
Evanston, IL
The Effect of Ventilation on Cerebral Oxygenation in the Sitting Position
Status: Enrolling
Updated: 1/15/2013
NorthShore University HealthSystem
mi
from
Evanston, IL
Click here to add this to my saved trials
Biomagnetic Signals of Intestinal Ischemia
Biomagnetic Signals of Intestinal Ischemia II
Status: Enrolling
Updated:  1/17/2013
Vanderbilt University Medical Center
mi
from
Nashville, TN
Biomagnetic Signals of Intestinal Ischemia
Biomagnetic Signals of Intestinal Ischemia II
Status: Enrolling
Updated: 1/17/2013
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Cangrelor Ticagrelor Transition Study
A Study of the Transition From Cangrelor to Ticagrelor, and Ticagrelor to Cangrelor in Patients With Coronary Artery Disease
Status: Enrolling
Updated:  1/17/2013
Fletcher Allen Health Care
mi
from
Burlington, VT
Cangrelor Ticagrelor Transition Study
A Study of the Transition From Cangrelor to Ticagrelor, and Ticagrelor to Cangrelor in Patients With Coronary Artery Disease
Status: Enrolling
Updated: 1/17/2013
Fletcher Allen Health Care
mi
from
Burlington, VT
Click here to add this to my saved trials
The Prediction of Extent and Risk Profile of Coronary Atherosclerosis and Their Changes During Lipid-lowering Therapy Based on Non-invasive Techniques
The Prediction of Extent and Risk Profile of Coronary Atherosclerosis (Examined by Intravascular Ultrasound, Virtual Histology and Optical Coherence Tomography) and Their Changes During Lipid-lowering Therapy Based on Non-invasive Techniques.
Status: Enrolling
Updated:  1/18/2013
Loyola University Hospital
mi
from
Maywood, IL
The Prediction of Extent and Risk Profile of Coronary Atherosclerosis and Their Changes During Lipid-lowering Therapy Based on Non-invasive Techniques
The Prediction of Extent and Risk Profile of Coronary Atherosclerosis (Examined by Intravascular Ultrasound, Virtual Histology and Optical Coherence Tomography) and Their Changes During Lipid-lowering Therapy Based on Non-invasive Techniques.
Status: Enrolling
Updated: 1/18/2013
Loyola University Hospital
mi
from
Maywood, IL
Click here to add this to my saved trials
The Prediction of Extent and Risk Profile of Coronary Atherosclerosis and Their Changes During Lipid-lowering Therapy Based on Non-invasive Techniques
The Prediction of Extent and Risk Profile of Coronary Atherosclerosis (Examined by Intravascular Ultrasound, Virtual Histology and Optical Coherence Tomography) and Their Changes During Lipid-lowering Therapy Based on Non-invasive Techniques.
Status: Enrolling
Updated:  1/18/2013
University of Iowa
mi
from
Iowa City, IA
The Prediction of Extent and Risk Profile of Coronary Atherosclerosis and Their Changes During Lipid-lowering Therapy Based on Non-invasive Techniques
The Prediction of Extent and Risk Profile of Coronary Atherosclerosis (Examined by Intravascular Ultrasound, Virtual Histology and Optical Coherence Tomography) and Their Changes During Lipid-lowering Therapy Based on Non-invasive Techniques.
Status: Enrolling
Updated: 1/18/2013
University of Iowa
mi
from
Iowa City, IA
Click here to add this to my saved trials
A Single Center Study to Establish the Imaging Protocol of 99mTc-EC-DG in Evaluating the Presence and Severity of Coronary Artery Disease (CAD)
A Single Center Pilot Study to Establish the 99mTc-EC-DG Imaging Protocol to Evaluate the Presence and Severity of Coronary Artery Disease
Status: Enrolling
Updated:  1/25/2013
Cardiovascular Imaging Technologies
mi
from
Kansas City, KA
A Single Center Study to Establish the Imaging Protocol of 99mTc-EC-DG in Evaluating the Presence and Severity of Coronary Artery Disease (CAD)
A Single Center Pilot Study to Establish the 99mTc-EC-DG Imaging Protocol to Evaluate the Presence and Severity of Coronary Artery Disease
Status: Enrolling
Updated: 1/25/2013
Cardiovascular Imaging Technologies
mi
from
Kansas City, KA
Click here to add this to my saved trials
A Study to Assess the Pharmacokinetics, Safety and Tolerability of Repeat Oral Doses of Darapladib (SB-480848) in Subjects With Severe Renal Impairment
An Open-Label, Non-Randomized, Pharmacokinetic and Safety Study of Multiple Oral Doses of SB-480848 in Healthy Subjects and in Subjects With Severe Renal Impairment
Status: Enrolling
Updated:  1/31/2013
GSK Investigational Site
mi
from
Jacksonville, FL
A Study to Assess the Pharmacokinetics, Safety and Tolerability of Repeat Oral Doses of Darapladib (SB-480848) in Subjects With Severe Renal Impairment
An Open-Label, Non-Randomized, Pharmacokinetic and Safety Study of Multiple Oral Doses of SB-480848 in Healthy Subjects and in Subjects With Severe Renal Impairment
Status: Enrolling
Updated: 1/31/2013
GSK Investigational Site
mi
from
Jacksonville, FL
Click here to add this to my saved trials
A Study to Assess the Pharmacokinetics, Safety and Tolerability of Repeat Oral Doses of Darapladib (SB-480848) in Subjects With Severe Renal Impairment
An Open-Label, Non-Randomized, Pharmacokinetic and Safety Study of Multiple Oral Doses of SB-480848 in Healthy Subjects and in Subjects With Severe Renal Impairment
Status: Enrolling
Updated:  1/31/2013
GSK Investigational Site
mi
from
Rochester, MN
A Study to Assess the Pharmacokinetics, Safety and Tolerability of Repeat Oral Doses of Darapladib (SB-480848) in Subjects With Severe Renal Impairment
An Open-Label, Non-Randomized, Pharmacokinetic and Safety Study of Multiple Oral Doses of SB-480848 in Healthy Subjects and in Subjects With Severe Renal Impairment
Status: Enrolling
Updated: 1/31/2013
GSK Investigational Site
mi
from
Rochester, MN
Click here to add this to my saved trials
A Pharmacodynamic Study With Ticagrelor in Hispanic Patients
A Randomized, Open-Label, Multiple Dose, Crossover, Multiple Center Study of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Hispanic Patients With Stable Coronary Artery Disease
Status: Enrolling
Updated:  2/4/2013
Clinical Research Facility
mi
from
San Diego, CA
A Pharmacodynamic Study With Ticagrelor in Hispanic Patients
A Randomized, Open-Label, Multiple Dose, Crossover, Multiple Center Study of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Hispanic Patients With Stable Coronary Artery Disease
Status: Enrolling
Updated: 2/4/2013
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
A Pharmacodynamic Study With Ticagrelor in Hispanic Patients
A Randomized, Open-Label, Multiple Dose, Crossover, Multiple Center Study of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Hispanic Patients With Stable Coronary Artery Disease
Status: Enrolling
Updated:  2/4/2013
Clinical Research Facility
mi
from
Fort Lauderdale, FL
A Pharmacodynamic Study With Ticagrelor in Hispanic Patients
A Randomized, Open-Label, Multiple Dose, Crossover, Multiple Center Study of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Hispanic Patients With Stable Coronary Artery Disease
Status: Enrolling
Updated: 2/4/2013
Clinical Research Facility
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
A Pharmacodynamic Study With Ticagrelor in Hispanic Patients
A Randomized, Open-Label, Multiple Dose, Crossover, Multiple Center Study of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Hispanic Patients With Stable Coronary Artery Disease
Status: Enrolling
Updated:  2/4/2013
Clinical Research Facility
mi
from
Baltimore, MD
A Pharmacodynamic Study With Ticagrelor in Hispanic Patients
A Randomized, Open-Label, Multiple Dose, Crossover, Multiple Center Study of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Hispanic Patients With Stable Coronary Artery Disease
Status: Enrolling
Updated: 2/4/2013
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Pharmacodynamic Study With Ticagrelor in Hispanic Patients
A Randomized, Open-Label, Multiple Dose, Crossover, Multiple Center Study of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Hispanic Patients With Stable Coronary Artery Disease
Status: Enrolling
Updated:  2/4/2013
Clinical Research Facility
mi
from
Teaneck, NJ
A Pharmacodynamic Study With Ticagrelor in Hispanic Patients
A Randomized, Open-Label, Multiple Dose, Crossover, Multiple Center Study of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Hispanic Patients With Stable Coronary Artery Disease
Status: Enrolling
Updated: 2/4/2013
Clinical Research Facility
mi
from
Teaneck, NJ
Click here to add this to my saved trials
A Pharmacodynamic Study With Ticagrelor in African American Patients
A Randomized, Open-Label, Multiple Dose, Crossover, Multiple Center Study of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in African American Patients With Stable Coronary Artery Disease
Status: Enrolling
Updated:  2/4/2013
Clinical Research Facility
mi
from
Newark, DE
A Pharmacodynamic Study With Ticagrelor in African American Patients
A Randomized, Open-Label, Multiple Dose, Crossover, Multiple Center Study of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in African American Patients With Stable Coronary Artery Disease
Status: Enrolling
Updated: 2/4/2013
Clinical Research Facility
mi
from
Newark, DE
Click here to add this to my saved trials
A Pharmacodynamic Study With Ticagrelor in African American Patients
A Randomized, Open-Label, Multiple Dose, Crossover, Multiple Center Study of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in African American Patients With Stable Coronary Artery Disease
Status: Enrolling
Updated:  2/4/2013
Clinical Research Facility
mi
from
Washington,
A Pharmacodynamic Study With Ticagrelor in African American Patients
A Randomized, Open-Label, Multiple Dose, Crossover, Multiple Center Study of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in African American Patients With Stable Coronary Artery Disease
Status: Enrolling
Updated: 2/4/2013
Clinical Research Facility
mi
from
Washington,
Click here to add this to my saved trials
A Pharmacodynamic Study With Ticagrelor in African American Patients
A Randomized, Open-Label, Multiple Dose, Crossover, Multiple Center Study of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in African American Patients With Stable Coronary Artery Disease
Status: Enrolling
Updated:  2/4/2013
Clinical Research Facility
mi
from
Fort Lauderdale, FL
A Pharmacodynamic Study With Ticagrelor in African American Patients
A Randomized, Open-Label, Multiple Dose, Crossover, Multiple Center Study of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in African American Patients With Stable Coronary Artery Disease
Status: Enrolling
Updated: 2/4/2013
Clinical Research Facility
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
A Pharmacodynamic Study With Ticagrelor in African American Patients
A Randomized, Open-Label, Multiple Dose, Crossover, Multiple Center Study of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in African American Patients With Stable Coronary Artery Disease
Status: Enrolling
Updated:  2/4/2013
Clinical Research Facility
mi
from
Atlanta, GA
A Pharmacodynamic Study With Ticagrelor in African American Patients
A Randomized, Open-Label, Multiple Dose, Crossover, Multiple Center Study of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in African American Patients With Stable Coronary Artery Disease
Status: Enrolling
Updated: 2/4/2013
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Pharmacodynamic Study With Ticagrelor in African American Patients
A Randomized, Open-Label, Multiple Dose, Crossover, Multiple Center Study of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in African American Patients With Stable Coronary Artery Disease
Status: Enrolling
Updated:  2/4/2013
Clinical Research Facility
mi
from
Baltimore, MD
A Pharmacodynamic Study With Ticagrelor in African American Patients
A Randomized, Open-Label, Multiple Dose, Crossover, Multiple Center Study of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in African American Patients With Stable Coronary Artery Disease
Status: Enrolling
Updated: 2/4/2013
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Pharmacodynamic Study With Ticagrelor in African American Patients
A Randomized, Open-Label, Multiple Dose, Crossover, Multiple Center Study of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in African American Patients With Stable Coronary Artery Disease
Status: Enrolling
Updated:  2/4/2013
Clinical Research Facility
mi
from
Houston, TX
A Pharmacodynamic Study With Ticagrelor in African American Patients
A Randomized, Open-Label, Multiple Dose, Crossover, Multiple Center Study of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in African American Patients With Stable Coronary Artery Disease
Status: Enrolling
Updated: 2/4/2013
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Sleep Apnea Intervention for Cardiovascular Disease Reduction
A Planning Study: Sleep Apnea Intervention for Cardiovascular Disease Reduction
Status: Enrolling
Updated:  2/6/2013
Brigham and Women's Hosp
mi
from
Boston, MA
Sleep Apnea Intervention for Cardiovascular Disease Reduction
A Planning Study: Sleep Apnea Intervention for Cardiovascular Disease Reduction
Status: Enrolling
Updated: 2/6/2013
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
To Estimate the Potential Effects of Repeat Doses of Darapladib on the Pharmacokinetics (PK) of Rosuvastatin as Well as Evaluating Safety and Tolerability in Healthy Volunteers
A Two-Part, Open-label, Sequential, Double Cohort, Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Rosuvastatin When Co Administered With Darapladib in Healthy Adult Subjects
Status: Enrolling
Updated:  2/7/2013
GSK Investigational Site
mi
from
Anaheim, CA
To Estimate the Potential Effects of Repeat Doses of Darapladib on the Pharmacokinetics (PK) of Rosuvastatin as Well as Evaluating Safety and Tolerability in Healthy Volunteers
A Two-Part, Open-label, Sequential, Double Cohort, Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Rosuvastatin When Co Administered With Darapladib in Healthy Adult Subjects
Status: Enrolling
Updated: 2/7/2013
GSK Investigational Site
mi
from
Anaheim, CA
Click here to add this to my saved trials
ADenosine Vasodilator Independent Stenosis Evaluation II - ADVISE II
A Prospective, Observational, Non-randomized, Double Blind, Global, Multi-center Registry With an Adaptive Design, Investigating the Diagnostic Utility of Instantaneous Wave-free Ratio™ (iFR®) in Assessing Coronary Stenosis Relevance.
Status: Enrolling
Updated:  2/15/2013
Cardiovascular Research of Florida
mi
from
Gainesville, FL
ADenosine Vasodilator Independent Stenosis Evaluation II - ADVISE II
A Prospective, Observational, Non-randomized, Double Blind, Global, Multi-center Registry With an Adaptive Design, Investigating the Diagnostic Utility of Instantaneous Wave-free Ratio™ (iFR®) in Assessing Coronary Stenosis Relevance.
Status: Enrolling
Updated: 2/15/2013
Cardiovascular Research of Florida
mi
from
Gainesville, FL
Click here to add this to my saved trials
ADenosine Vasodilator Independent Stenosis Evaluation II - ADVISE II
A Prospective, Observational, Non-randomized, Double Blind, Global, Multi-center Registry With an Adaptive Design, Investigating the Diagnostic Utility of Instantaneous Wave-free Ratio™ (iFR®) in Assessing Coronary Stenosis Relevance.
Status: Enrolling
Updated:  2/15/2013
St Johns Hospital/ Prairie Education and Research
mi
from
Springfield, IL
ADenosine Vasodilator Independent Stenosis Evaluation II - ADVISE II
A Prospective, Observational, Non-randomized, Double Blind, Global, Multi-center Registry With an Adaptive Design, Investigating the Diagnostic Utility of Instantaneous Wave-free Ratio™ (iFR®) in Assessing Coronary Stenosis Relevance.
Status: Enrolling
Updated: 2/15/2013
St Johns Hospital/ Prairie Education and Research
mi
from
Springfield, IL
Click here to add this to my saved trials
ADenosine Vasodilator Independent Stenosis Evaluation II - ADVISE II
A Prospective, Observational, Non-randomized, Double Blind, Global, Multi-center Registry With an Adaptive Design, Investigating the Diagnostic Utility of Instantaneous Wave-free Ratio™ (iFR®) in Assessing Coronary Stenosis Relevance.
Status: Enrolling
Updated:  2/15/2013
Univ of Minnesota
mi
from
Minneapolis, MN
ADenosine Vasodilator Independent Stenosis Evaluation II - ADVISE II
A Prospective, Observational, Non-randomized, Double Blind, Global, Multi-center Registry With an Adaptive Design, Investigating the Diagnostic Utility of Instantaneous Wave-free Ratio™ (iFR®) in Assessing Coronary Stenosis Relevance.
Status: Enrolling
Updated: 2/15/2013
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
ADenosine Vasodilator Independent Stenosis Evaluation II - ADVISE II
A Prospective, Observational, Non-randomized, Double Blind, Global, Multi-center Registry With an Adaptive Design, Investigating the Diagnostic Utility of Instantaneous Wave-free Ratio™ (iFR®) in Assessing Coronary Stenosis Relevance.
Status: Enrolling
Updated:  2/15/2013
Stony Brook Medicine
mi
from
Stony Brook, NY
ADenosine Vasodilator Independent Stenosis Evaluation II - ADVISE II
A Prospective, Observational, Non-randomized, Double Blind, Global, Multi-center Registry With an Adaptive Design, Investigating the Diagnostic Utility of Instantaneous Wave-free Ratio™ (iFR®) in Assessing Coronary Stenosis Relevance.
Status: Enrolling
Updated: 2/15/2013
Stony Brook Medicine
mi
from
Stony Brook, NY
Click here to add this to my saved trials
ADenosine Vasodilator Independent Stenosis Evaluation II - ADVISE II
A Prospective, Observational, Non-randomized, Double Blind, Global, Multi-center Registry With an Adaptive Design, Investigating the Diagnostic Utility of Instantaneous Wave-free Ratio™ (iFR®) in Assessing Coronary Stenosis Relevance.
Status: Enrolling
Updated:  2/15/2013
University of North Carolina Hospital
mi
from
Chapel Hill, NC
ADenosine Vasodilator Independent Stenosis Evaluation II - ADVISE II
A Prospective, Observational, Non-randomized, Double Blind, Global, Multi-center Registry With an Adaptive Design, Investigating the Diagnostic Utility of Instantaneous Wave-free Ratio™ (iFR®) in Assessing Coronary Stenosis Relevance.
Status: Enrolling
Updated: 2/15/2013
University of North Carolina Hospital
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
ADenosine Vasodilator Independent Stenosis Evaluation II - ADVISE II
A Prospective, Observational, Non-randomized, Double Blind, Global, Multi-center Registry With an Adaptive Design, Investigating the Diagnostic Utility of Instantaneous Wave-free Ratio™ (iFR®) in Assessing Coronary Stenosis Relevance.
Status: Enrolling
Updated:  2/15/2013
Forsyth Medical Center
mi
from
Winston-Salem, NC
ADenosine Vasodilator Independent Stenosis Evaluation II - ADVISE II
A Prospective, Observational, Non-randomized, Double Blind, Global, Multi-center Registry With an Adaptive Design, Investigating the Diagnostic Utility of Instantaneous Wave-free Ratio™ (iFR®) in Assessing Coronary Stenosis Relevance.
Status: Enrolling
Updated: 2/15/2013
Forsyth Medical Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials